These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32963047)

  • 41. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.
    Reinisch W; Panés J; Khurana S; Toth G; Hua F; Comer GM; Hinz M; Page K; O'Toole M; Moorehead TM; Zhu H; Sun Y; Cataldi F
    Gut; 2015 Jun; 64(6):894-900. PubMed ID: 25567115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Double-blind, Randomized Controlled Trial of Ciplukan (Physalis angulata Linn) Extract on Skin Fibrosis, Inflammatory, Immunology, and Fibrosis Biomarkers in Scleroderma Patients.
    Dewi S; Isbagio H; Purwaningsih EH; Kertia N; Setiabudy R; Setiati S
    Acta Med Indones; 2019 Oct; 51(4):303-310. PubMed ID: 32041913
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
    Spiera R; Hummers L; Chung L; Frech TM; Domsic R; Hsu V; Furst DE; Gordon J; Mayes M; Simms R; Lafyatis R; Martyanov V; Wood T; Whitfield ML; Constantine S; Lee E; Dgetluck N; White B
    Arthritis Rheumatol; 2020 Aug; 72(8):1350-1360. PubMed ID: 32336038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
    Nagaraja V; Spino C; Bush E; Tsou PS; Domsic RT; Lafyatis R; Frech T; Gordon JK; Steen VD; Khanna D
    Arthritis Res Ther; 2019 Sep; 21(1):202. PubMed ID: 31481106
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
    Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial.
    Ebata S; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Yoshihide A; Yoshizaki A; Sato S
    Rheumatology (Oxford); 2022 Nov; 61(11):4364-4373. PubMed ID: 35136981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation.
    Mattoo H; Bangari DS; Cummings S; Humulock Z; Habiel D; Xu EY; Pate N; Resnick R; Savova V; Qian G; Beil C; Rao E; Nestle FO; Bryce PJ; Subramaniam A
    Am J Respir Cell Mol Biol; 2023 Oct; 69(4):404-421. PubMed ID: 37369139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.
    Utsunomiya A; Hasegawa M; Oyama N; Asano Y; Endo H; Fujimoto M; Goto D; Ishikawa O; Kawaguchi Y; Kuwana M; Ogawa F; Takahashi H; Tanaka S; Sato S; Takehara K; Ihn H
    Mod Rheumatol; 2021 Jan; 31(1):162-170. PubMed ID: 32243215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
    Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
    Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis.
    You H; Xu D; Hou Y; Zhou J; Wang Q; Li M; Zeng X
    Rheumatology (Oxford); 2021 May; 60(5):2472-2477. PubMed ID: 33188425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
    Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
    Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study.
    Cellier C; Bouma G; van Gils T; Khater S; Malamut G; Crespo L; Collin P; Green PHR; Crowe SE; Tsuji W; Butz E; Cerf-Bensussan N; Macintyre E; Parnes JR; Leon F; Hermine O; Mulder CJ;
    Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):960-970. PubMed ID: 31494097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
    Arnold MB; Khanna D; Denton CP; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE; Pope JE
    Rheumatology (Oxford); 2018 Jan; 57(1):152-157. PubMed ID: 29077900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical characteristics and outcomes of 566 Thais with systemic sclerosis: A cohort study.
    Foocharoen C; Peansukwech U; Mahakkanukrauh A; Suwannaroj S; Pongkulkiat P; Khamphiw P; Nanagara R
    Int J Rheum Dis; 2020 Jul; 23(7):945-957. PubMed ID: 32420701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
    Melsens K; De Keyser F; Decuman S; Brusselle G; De Pauw M; Deschepper E; De Wilde K; Elewaut D; Piette Y; Vandecasteele E; Smith V
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):148-151. PubMed ID: 27463733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.